JP2022000001A - Composition containing n-acetyl glucosamine, proteoglycan and extract powder of giant knotweed (polygonum sachalinense fr.schm) - Google Patents
Composition containing n-acetyl glucosamine, proteoglycan and extract powder of giant knotweed (polygonum sachalinense fr.schm) Download PDFInfo
- Publication number
- JP2022000001A JP2022000001A JP2020105714A JP2020105714A JP2022000001A JP 2022000001 A JP2022000001 A JP 2022000001A JP 2020105714 A JP2020105714 A JP 2020105714A JP 2020105714 A JP2020105714 A JP 2020105714A JP 2022000001 A JP2022000001 A JP 2022000001A
- Authority
- JP
- Japan
- Prior art keywords
- cellulose
- proteoglycan
- extract powder
- composition
- acetylglucosamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 title claims abstract description 24
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 title claims abstract description 24
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 title claims abstract description 24
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 title claims abstract description 24
- 229950006780 n-acetylglucosamine Drugs 0.000 title claims abstract description 24
- 239000000843 powder Substances 0.000 title claims abstract description 24
- 244000153955 Reynoutria sachalinensis Species 0.000 title abstract description 22
- 229920002678 cellulose Polymers 0.000 claims abstract description 33
- 239000001913 cellulose Substances 0.000 claims abstract description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 241001289503 Fallopia sachalinensis Species 0.000 claims 2
- 238000010521 absorption reaction Methods 0.000 abstract description 10
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004040 coloring Methods 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 238000002156 mixing Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000000845 cartilage Anatomy 0.000 description 6
- 235000013305 food Nutrition 0.000 description 4
- 230000037231 joint health Effects 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- -1 brighteners Substances 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229940016409 methylsulfonylmethane Drugs 0.000 description 2
- 229940114496 olive leaf extract Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000272185 Falco Species 0.000 description 1
- 229920003114 HPC-L Polymers 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 241000278713 Theora Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000020204 cat's claw extract Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 210000002184 nasal cartilage Anatomy 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- DVQHRBFGRZHMSR-UHFFFAOYSA-N sodium methyl 2,2-dimethyl-4,6-dioxo-5-(N-prop-2-enoxy-C-propylcarbonimidoyl)cyclohexane-1-carboxylate Chemical compound [Na+].C=CCON=C(CCC)[C-]1C(=O)CC(C)(C)C(C(=O)OC)C1=O DVQHRBFGRZHMSR-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
Abstract
Description
本発明は、着色及び吸湿の少ない、Ｎ−アセチルグルコサミン、プロテオグリカン及びオオイタドリエキス末含有組成物に関する。 The present invention relates to a composition containing N-acetylglucosamine, proteoglycan and Reynoutria sachalinensis extract powder, which is less colored and absorbs moisture.
膝や肘等の人の関節部には軟骨があって、骨と骨との間でのクッション材の役割を果たしているが、軟骨が減少すると変形性関節炎の原因になる。厚生労働省の国民生活基礎調査等によると、高齢者の要支援・要介護の要因には、変形性膝関節症などの関節の健康に関わるものが挙げられており、変形性膝関節症の有病率は加齢とともに増加するため、関節の健康を維持・増進することは、高齢者のＱＯＬ向上の点からも有用である。 There is cartilage in human joints such as knees and elbows, which acts as a cushioning material between bones, but when cartilage is reduced, it causes degenerative arthritis. According to the National Life Basic Survey of the Ministry of Health, Labor and Welfare, factors related to joint health such as knee osteoarthritis are listed as factors requiring support and care for the elderly, and there is knee osteoarthritis. Since the morbidity increases with aging, maintaining and improving joint health is also useful in terms of improving the QOL of the elderly.
こうした背景のもと、関節の健康を維持・増進するための食品成分が各種上市されており、Ｎ−アセチルグルコサミン（ＮＡＧ）、プロテオグリカン、オオイタドリエキス末のほか、グルコサミン、コンドロイチン、ヒアルロン酸、コラーゲン、メチルスルホニルメタン（ＭＳＭ）、エラスチン、オリーブ葉エキス、キャッツクローエキスなどが利用されている（特許文献１〜特許文献４）。 Against this background, various food ingredients for maintaining and promoting joint health have been put on the market. In addition to N-acetylglucosamine (NAG), proteoglycan, and olive leaf extract powder, glucosamine, chondroitin, hyaluronic acid, collagen, etc. Methylsulfonylmethane (MSM), elastin, olive leaf extract, cat's claw extract and the like are used (Patent Documents 1 to 4).
Ｎ−アセチルグルコサミンは、軟骨成分のヒアルロン酸を構成する主成分であり、関節軟骨においてグリコサミノグリカン（ヒアルロン酸等）などを増加させ、関節中のII型コラーゲンの分解を抑制することにより、関節軟骨の代謝を正常化する。Ｎ−アセチルグルコサミンは、エビやカニ等の甲殻類の外殻などを起源原料として製造される。 N-acetylglucosamine is a main component of hyaluronic acid, which is a cartilage component. It increases glycosaminoglycan (hyaluronic acid, etc.) in articular cartilage and suppresses the decomposition of type II collagen in joints. Normalizes the metabolism of articular cartilage. N-Acetylglucosamine is produced from the outer shell of crustaceans such as shrimp and crab as a raw material.
プロテオグリカンは、軟骨組織の主成分のひとつであり、タンパク質をコアとしてコンドロイチン硫酸などのグリコサミノグリカンが共有結合した化合物であって、II型コラーゲンとの架橋により軟骨組織を維持する。プロテオグリカンは、動物の軟骨や皮膚に存在し、サケ鼻軟骨などを起源原料として製造される Proteoglycan is one of the main components of cartilage tissue, is a compound in which glycosaminoglycan such as chondroitin sulfate is covalently bonded with a protein as a core, and maintains cartilage tissue by cross-linking with type II collagen. Proteoglycan is present in animal cartilage and skin, and is manufactured from salmon nasal cartilage as a raw material.
オオイタドリエキス末は、ＴＮＦ−αを介した抗炎症作用、ＣＯＸを介した鎮痛作用により、関節の炎症や痛みの軽減に効果がある。オオイタドリエキス末は、タデ科の多年生植物オオイタドリを起源原料として製造される。 Reynoutria sachalinensis extract powder is effective in reducing joint inflammation and pain due to its anti-inflammatory effect mediated by TNF-α and its analgesic effect mediated by COX. Reynoutria sachalinensis extract powder is produced from the perennial plant Reynoutria sachalinensis of the Polygonaceae family as a raw material.
上に述べたように、Ｎ−アセチルグルコサミン、プロテオグリカン、オオイタドリエキス末は、それぞれ、関節の健康を維持・増進するための食品成分として使用されているが、関節保護作用におけるメカニズムが互いに異なっているので、これらを複数組み合わせることでより高い効果が期待できる。
しかし、従来、これら３成分を同時に含有する組成物については報告がない。そこで、本発明者らが、Ｎ−アセチルグルコサミン、プロテオグリカン及びオオイタドリエキス末
の３成分を組み合わせて配合したところ、これらの３成分を同時に配合した組成物は、経時的に着色及び吸湿が生じて安定性が低下し、食品として提供するために十分な品質が得られないという問題があることが判明した。
As mentioned above, N-acetylglucosamine, proteoglycan, and Reynoutria sachalinensis extract powders are used as food ingredients to maintain and promote joint health, but their mechanisms in joint protection are different from each other. Therefore, a higher effect can be expected by combining a plurality of these.
However, conventionally, there is no report on a composition containing these three components at the same time. Therefore, when the present inventors blended three components of N-acetylglucosamine, proteoglycan, and powder of Reynoutria sachalinensis in combination, the composition containing these three components at the same time was stable due to coloration and moisture absorption over time. It has been found that there is a problem that the sex is deteriorated and sufficient quality cannot be obtained for provision as food.
本発明の課題は、Ｎ−アセチルグルコサミン、プロテオグリカン及びオオイタドリエキス末の３成分を含有し、かつ経時的な着色及び吸湿の少ない、組成物を提供することである。 An object of the present invention is to provide a composition containing three components of N-acetylglucosamine, proteoglycan and Reynoutria sachalinensis extract powder, and having less coloring and moisture absorption over time.
上記の課題は、Ｎ−アセチルグルコサミン、プロテオグリカン及びオオイタドリエキス末を含有する、以下の組成物によって解決することができる。
（１）Ｎ−アセチルグルコサミン、プロテオグリカン、オオイタドリエキス末を含み、さらにセルロース又はセルロース誘導体を含む組成物。
（２）Ｎ−アセチルグルコサミンを５〜７０質量％、プロテオグリカンを０．２〜３．６質量％、オオイタドリエキス末を５〜３０質量％含む、（１）に記載の組成物。
（３）前記セルロース誘導体が、ヒドロキシプロピルメチルセルロース又はヒドロキシプロピルセルロースである（１）又は（２）に記載の組成物。
（４）セルロース又はセルロース誘導体を２〜６７質量％含む、（１）〜（３）のいずれかに記載の組成物。
（５）前記セルロースの平均粒子径が９０μｍ以下である、（１）〜（４）のいずれかに記載の組成物。
（６）温度４０℃、相対湿度７５％で３日間の保存による色差（ΔE）が１０以下である、（１）〜（５）のいずれかに記載の組成物。
（７）温度４０℃、相対湿度７５％で３日間の保存による水分量が２．６％以下である、（１）〜（６）のいずれかに記載の組成物。
The above problem can be solved by the following composition containing N-acetylglucosamine, proteoglycan and Reynoutria sachalinensis extract powder.
(1) A composition containing N-acetylglucosamine, proteoglycan, and Reynoutria sachalinensis extract powder, and further containing cellulose or a cellulose derivative.
(2) The composition according to (1), which contains 5 to 70% by mass of N-acetylglucosamine, 0.2 to 3.6% by mass of proteoglycan, and 5 to 30% by mass of Reynoutria sachalinensis extract powder.
(3) The composition according to (1) or (2), wherein the cellulose derivative is hydroxypropylmethyl cellulose or hydroxypropyl cellulose.
(4) The composition according to any one of (1) to (3), which contains 2 to 67% by mass of cellulose or a cellulose derivative.
(5) The composition according to any one of (1) to (4), wherein the average particle size of the cellulose is 90 μm or less.
(6) The composition according to any one of (1) to (5), wherein the color difference (ΔE) after storage at a temperature of 40 ° C. and a relative humidity of 75% for 3 days is 10 or less.
(7) The composition according to any one of (1) to (6), wherein the temperature is 40 ° C., the relative humidity is 75%, and the water content after storage for 3 days is 2.6% or less.
本発明のＮ−アセチルグルコサミン、プロテオグリカン及びオオイタドリエキス末含有組成物は、さらにセルロース又はセルロース誘導体を含むことによって、経時的な着色や吸湿による品質の低下が低減されて安定性が高く、保存性に優れているため、継続して摂取することができ、特に経口摂取する飲食品用の組成物として極めて有用である。 The composition containing N-acetylglucosamine, proteoglycan and Reynoutria sachalinensis extract powder of the present invention further contains cellulose or a cellulose derivative, so that deterioration of quality due to coloring and moisture absorption over time is reduced, and the composition has high stability and storage stability. Due to its superiority, it can be continuously ingested and is extremely useful as a composition for foods and drinks to be ingested orally.
以下、本発明の好適な実施形態について具体的に説明する。 Hereinafter, preferred embodiments of the present invention will be specifically described.
本発明の組成物は、Ｎ−アセチルグルコサミン、プロテオグリカン、オオイタドリエキス末、及びセルロース又はセルロース誘導体を少なくとも含むものであり、これらの３成分が含まれている限り、各成分の相対的な配合量については、特段の制限はないが、通常、Ｎ−アセチルグルコサミンは、好ましくは５〜７０質量％、より好ましくは１０〜６０質量％の範囲で配合され、プロテオグリカンは、好ましくは０．２〜３．６質量％、より好ましくは１〜２質量％の範囲で配合され、オオイタドリエキス末は、好ましくは５〜３０質量％、より好ましくは１０〜２７質量％の範囲で配合される。 The composition of the present invention contains at least N-acetylglucosamine, proteoglycan, powdered Reynoutria sachalinensis, and cellulose or a cellulose derivative, and as long as these three components are contained, the relative blending amount of each component is Is not particularly limited, but usually N-acetylglucosamine is blended in the range of preferably 5 to 70% by mass, more preferably 10 to 60% by mass, and proteoglycan is preferably 0.2 to 3. It is blended in the range of 6% by mass, more preferably 1 to 2% by mass, and the powder of Reynoutria sachalinensis is preferably blended in the range of 5 to 30% by mass, more preferably 10 to 27% by mass.
また、本発明の組成物において、セルロース又はセルロース誘導体は、好ましくは２〜６７質量％、より好ましくは１２〜２６質量％の範囲で配合される。本発明の組成物においては、Ｎ−アセチルグルコサミン、プロテオグリカン及びオオイタドリエキス末が有効成分であって、セルロース又はセルロース誘導体は、その安定剤として使用されるものであるので、セルロース又はセルロース誘導体は、安定剤としての役割を果たす範囲であれば、その使用量をむやみに増やす必要はない。 Further, in the composition of the present invention, the cellulose or the cellulose derivative is preferably blended in the range of 2 to 67% by mass, more preferably 12 to 26% by mass. In the composition of the present invention, N-acetylglucosamine, proteoglycan and oyster extract powder are active ingredients, and cellulose or a cellulose derivative is used as a stabilizer thereof, so that cellulose or a cellulose derivative is stable. As long as it plays a role as an agent, it is not necessary to increase the amount used unnecessarily.
セルロース誘導体としては、公知のセルロース誘導体を特に限定なく使用することができるが、なかでも、ヒドロキシプロピルメチルセルロース（ＨＰＭＣ）、ヒドロキシメチルセルロース（ＨＭＣ）、ヒドロキシエチルセルロース（ＨＥＭ）、ヒドロキシプロピルセルロース（ＨＰＣ）又はカルボキシメチルセルロース（ＣＭＣ）が好ましく、ヒドロキシプロピルメチルセルロース（ＨＰＭＣ）又はヒドロキシプロピルセルロース（ＨＰＣ）が特に好ましい。 As the cellulose derivative, known cellulose derivatives can be used without particular limitation, and among them, hydroxypropylmethyl cellulose (HPMC), hydroxymethyl cellulose (HMC), hydroxyethyl cellulose (HEM), hydroxypropyl cellulose (HPC) or carboxy. Methyl cellulose (CMC) is preferred, and hydroxypropyl methyl cellulose (HPMC) or hydroxypropyl cellulose (HPC) is particularly preferred.
使用するセルロース又はセルロース誘導体としては、粉末状の市販品を特に制限なく使用することができるが、特に平均粒子径が９０μｍ以下であるものが好ましい。 As the cellulose or the cellulose derivative to be used, a commercially available powdered product can be used without particular limitation, but those having an average particle size of 90 μm or less are particularly preferable.
本発明の組成物の態様としては、経口摂取に適した形態であれば特に制限はないが、例えば、粉末状、粒状、顆粒状、錠剤状、棒状、板状、ブロック状、固形状、丸状、ハードカプセルやソフトカプセルのようなカプセル状、カプレット状、タブレット状、チュアブル状、スティック状等の各形態が挙げられる。 The aspect of the composition of the present invention is not particularly limited as long as it is in a form suitable for oral ingestion, but for example, powder, granule, granule, tablet, rod, plate, block, solid, or round. Each form includes a shape, a capsule shape such as a hard capsule or a soft capsule, a caplet shape, a tablet shape, a chewable shape, and a stick shape.
本発明の組成物には、さらに効果を損なわない範囲において、通常飲食品に配合される任意の成分を加えることができる。例えば、賦形剤、結合剤、光沢剤、滑沢剤、安定剤、増粘剤、乳化剤、酸化防止剤、ｐH調整剤、着色料、香料、添加剤、甘味料、酸味料、その他の有効成分（生理活性成分）などを挙げることができる。 To the composition of the present invention, any component usually blended in foods and drinks can be added as long as the effect is not further impaired. For example, excipients, binders, brighteners, lubricants, stabilizers, thickeners, emulsifiers, antioxidants, pH regulators, colorants, fragrances, additives, sweeteners, acidulants, and other effective ingredients. Ingredients (physiologically active ingredients) and the like can be mentioned.
本発明の組成物において、温度４０℃、相対湿度７５％で３日間の保存による色差（ΔE）が１０以下であることが好ましい。１０を超えると、経時的な着色
が目視で認識可能となり、商品価値が低下するなどの点で好ましくない。
In the composition of the present invention, the color difference (ΔE) after storage at a temperature of 40 ° C. and a relative humidity of 75% for 3 days is preferably 10 or less. If it exceeds 10, coloring over time becomes visually recognizable, which is not preferable in that the commercial value is lowered.
本発明の組成物において、温度４０℃、相対湿度７５％で３日間の保存による水分量が２．６％以下であることが好ましい。２．６％を超えると、保存中における経時的な着色が加速し、保存中における有効成分の安定性低下が加速する点で好ましくない。また、混合粉末の流動性が低下するために作業性が悪くなるなどの点で好ましくない。 In the composition of the present invention, the water content after storage at a temperature of 40 ° C. and a relative humidity of 75% for 3 days is preferably 2.6% or less. If it exceeds 2.6%, coloring over time during storage is accelerated, and the decrease in stability of the active ingredient during storage is accelerated, which is not preferable. Further, it is not preferable because the fluidity of the mixed powder is lowered and the workability is deteriorated.
実施例１〜３及び比較例１〜５
方法：下記表１に示した量の各成分の粉末を合計１０ｇとなるように混合して、実施例及び比較例用の試料を調製した。
Examples 1 to 3 and Comparative Examples 1 to 5
Method: Samples for Examples and Comparative Examples were prepared by mixing the powders of each component in the amounts shown in Table 1 below so as to make a total of 10 g.
実施例及び比較例の試料の調製に使用した製品は、以下のとおりである。
・オオイタドリエキス末（ユニアル製、商品名「オオイタドリエキス末」）
・Ｎ−アセチルグルコサミン（焼津水産化学工業製、商品名「ビューティーシュガー」）
・プロテオグリカン（一丸ファルコス製、商品名「プロテオグリカンＦ」）
・セルロース（旭化成製、商品名「セオラス」）
・ＨＰＭＣ（信越化学工業製、商品名「メトローズ」）
・ＨＰＣ（日本曹達製、商品名「ＨＰＣ−Ｌ」）
・還元麦芽糖水飴（三菱商事ライフサイエンス製、商品名「アマルティ ＭＲ５０」）
・エリスリトール（三菱ケミカルフーズ製、商品名「エリスリトール」）
・乳糖（ＤＦＥ Ｐｈａｒｍａ製、商品名「Ｐｈａｒｍａｔｏｓｅ ２００Ｍ」）
・デキストリン（松谷化学工業製、商品名「ＴＫ−１６」）
The products used to prepare the samples of Examples and Comparative Examples are as follows.
・ Reynoutria sachalinensis extract powder (Uniaru, trade name “Reynoutria sachalinensis extract powder”)
・ N-Acetylglucosamine (manufactured by YAIZU SUISAN CHEMICAL INDUSTRIES, product name "Beauty Sugar")
・ Proteoglycan (made by Ichimaru Falcos, product name "Proteoglycan F")
・ Cellulose (Asahi Kasei, trade name "Theoras")
・ HPMC (manufactured by Shin-Etsu Chemical Co., Ltd., product name "Metro's")
・ HPC (manufactured by Nippon Soda, product name "HPC-L")
・ Reduced maltose starch syrup (manufactured by Mitsubishi Corporation Life Sciences, product name "Amarti MR50")
・ Erythritol (manufactured by Mitsubishi Chemical Foods, trade name "erythritol")
・ Lactose (manufactured by DFE Pharma, trade name "Pharmatose 200M")
・ Dextrin (manufactured by Matsutani Chemical Industry, trade name "TK-16")
これらの試料を、温度４０℃、相対湿度７５％の保存条件で３日間保管し、以下の方法で色差と水分量を測定した。
色差は分光色彩計（日本電色工業製、ＳＥ−６０００)を使用し、試料の色彩をＬ*ａ*ｂ*表色系で測定した。この分光色彩計では、開始時と保存後の色差ΔEが、下記数式１により算出して表示される。
数式１：ΔＥ＝［（ΔＬ*）2+（Δａ*）2+（Δｂ*）2］1/2
水分量は、赤外線乾燥水分計（Ｍｅｔｔｌｅｒ Ｔｏｌｅｄｏ製、ＨＲ８３−Ｐ）を使用し、１０５℃２０分間の重量変化により測定した。結果を表１に示した。
These samples were stored for 3 days under a storage condition of a temperature of 40 ° C. and a relative humidity of 75%, and the color difference and the water content were measured by the following methods.
The color difference was measured by using a spectrocolorimeter (SE-6000 manufactured by Nippon Denshoku Kogyo Co., Ltd.) and measuring the color of the sample with the L * a * b * color system. In this spectrocolorimeter, the color difference ΔE at the start and after storage is calculated and displayed by the following formula 1.
Formula 1: ΔE = [(ΔL *) 2 + (Δa *) 2 + (Δb *) 2 ] 1/2
The water content was measured by a weight change at 105 ° C. for 20 minutes using an infrared dry moisture meter (manufactured by Mettler Toledo, HR83-P). The results are shown in Table 1.
上記条件で保存した試料の試験開始前と比較した３日後の色差ΔEが１０以下で、水分量が２．６％以下であれば、市販品として十分な安定性があるといえる。 If the color difference ΔE 3 days after the start of the test and the water content of the sample stored under the above conditions is 10 or less and the water content is 2.6% or less, it can be said that the sample has sufficient stability as a commercial product.
表１の結果から、上記条件下でＮ−アセチルグルコサミン、プロテオグリカン及びオオイタドリエキス末を含有する組成物は着色及び吸湿を示す（比較例１）が、還元麦芽糖水飴（比較例２）、エリスリトール（比較例３）、乳糖（比較例４）及びデキストリン（比較例５）のような添加物を添加しても、これを改善することができないのに対して、セルロース及びセルロース誘導体を添加した場合には、着色及び吸湿が大きく改善され、安定性の高い組成物を提供できることがわかる。 From the results in Table 1, the composition containing N-acetylglucosamine, proteoglycan and Oitadori extract powder under the above conditions showed coloring and moisture absorption (Comparative Example 1), but reduced maltose starch syrup (Comparative Example 2) and erythritol (Comparative Example 2). Additives such as Example 3), lactose (Comparative Example 4) and dextrin (Comparative Example 5) cannot improve this, whereas when cellulose and cellulose derivatives are added, they cannot be improved. It can be seen that coloring and moisture absorption are greatly improved, and a highly stable composition can be provided.
次に、実施例１で使用したセルロースの平均粒子径を変えて、同じ条件で、色差と水分量を測定した。結果を表２に示す。 Next, the average particle size of the cellulose used in Example 1 was changed, and the color difference and the water content were measured under the same conditions. The results are shown in Table 2.
使用するセルロースの平均粒子径が小さいものや大きいものに変えても、着色及び吸湿が少ない安定な組成物を得ることができる。 A stable composition with less coloring and moisture absorption can be obtained even if the average particle size of the cellulose used is changed to one having a small particle size or one having a large particle size.
次に、使用するオオイタドリエキス末の配合量を変え、同じ条件で、色差と水分量を測定した。結果を表３に示す。 Next, the blending amount of the powdered Reynoutria sachalinensis used was changed, and the color difference and the water content were measured under the same conditions. The results are shown in Table 3.
本発明の組成物は、組成物におけるオオイタドリエキス末の配合量を変化させても、着色及び吸湿が少ない安定な組成物を得ることができる。 The composition of the present invention can obtain a stable composition with less coloring and moisture absorption even if the blending amount of the powder of Reynoutria sachalinensis in the composition is changed.
また、オオイタドリエキス末の配合量を実施例１の量に固定した上で、Ｎ−アセチルグルコサミンとプロテオグリカンの配合量を変化させた試料を調製し、同じ条件で、色差と水分量を測定した。結果を表４に示す。 In addition, after fixing the blending amount of Reynoutria sachalinensis extract powder to the amount of Example 1, samples in which the blending amounts of N-acetylglucosamine and proteoglycan were changed were prepared, and the color difference and the water content were measured under the same conditions. The results are shown in Table 4.
Ｎ−アセチルグルコサミンとプロテオグリカンの配合量を変化させても、着色及び吸湿が少ない安定な組成物を得ることができる。 Even if the blending amounts of N-acetylglucosamine and proteoglycan are changed, a stable composition with less coloring and less moisture absorption can be obtained.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020105714A JP2022000001A (en) | 2020-06-19 | 2020-06-19 | Composition containing n-acetyl glucosamine, proteoglycan and extract powder of giant knotweed (polygonum sachalinense fr.schm) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020105714A JP2022000001A (en) | 2020-06-19 | 2020-06-19 | Composition containing n-acetyl glucosamine, proteoglycan and extract powder of giant knotweed (polygonum sachalinense fr.schm) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2022000001A true JP2022000001A (en) | 2022-01-04 |
Family
ID=79242073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020105714A Pending JP2022000001A (en) | 2020-06-19 | 2020-06-19 | Composition containing n-acetyl glucosamine, proteoglycan and extract powder of giant knotweed (polygonum sachalinense fr.schm) |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2022000001A (en) |
-
2020
- 2020-06-19 JP JP2020105714A patent/JP2022000001A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5324000B1 (en) | Composition containing imidazole peptide and quercetin glycoside | |
| JP4652486B2 (en) | Formulation for oral administration containing chondroitin sulfate-containing cartilage aqueous solvent extract and quercetin glycoside | |
| JP4818177B2 (en) | Bone and muscle enhancement promoting composition for elderly | |
| EP2435021B1 (en) | Use of a glycosaminoglycan fixed combination and chewable composition comprising said fixed combination | |
| JP2017061576A (en) | Solid composition | |
| JP2006342085A (en) | Gip secretion inhibitor | |
| JP5578955B2 (en) | Hyaluronic acid and glucosamine-containing tablets | |
| JP2016036335A (en) | Gel composition | |
| JP5204578B2 (en) | Joint pain improving composition, joint pain improving agent, or food | |
| JP2011050253A (en) | Solid food composition containing hyaluronic acid, elastin and ceramide | |
| JP2022000001A (en) | Composition containing n-acetyl glucosamine, proteoglycan and extract powder of giant knotweed (polygonum sachalinense fr.schm) | |
| JP2023099723A (en) | Locomotive syndrome improvement composition | |
| JP2007099653A (en) | Arthrodynia ameliorator | |
| JP6923065B1 (en) | Oral solid composition | |
| JP5123574B2 (en) | Hyaluronic acid production enhancer | |
| DE19859771C1 (en) | Water-soluble, stable pyruvic acid (salt) -containing formulation | |
| JP2022096826A (en) | Oral composition | |
| JP6761363B2 (en) | Powdered beverage composition and its uses | |
| KR20180012596A (en) | Composition containing pineapple ceramide with high level of stability | |
| JP2005154281A (en) | Medicinal composition for prophylaxis and therapy of arthropathy | |
| WO2013129551A1 (en) | Solid composition | |
| JP6867200B2 (en) | Proteoglycan-containing easily disintegrating tablets | |
| JP2017163999A (en) | Flavor improving method and flavor improving composition comprising n-acetylglucosamine | |
| WO2021090552A1 (en) | Enteric preparation containing lactoferrin | |
| JP2023124935A (en) | Composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230203 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240111 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240321 |